Bastardot, François

Bochud, Murielle

Marques-Vidal Pedro, Manuel

Paccaud, Fred

Preisig, Martin

Schmid, Rémy

Vollenweider, Peter

von Känel, Roland

Waeber, Gérard

Marques-Vidal, P

Schmid, R

Bochud, M

Bastardot, F

von Känel, R

Paccaud, F

Preisig, M

Waeber, G

Vollenweider, P

Bern Open Repository and Information System (BORIS)

Adipocytokines and inflammatory biomarkers are independent predictors of type 2 diabetes. The CoLaus study.

Serveur académique lausannois

2025   Adipocytokines and inflammatory biomarkers are independent predictors of type 2 diabetes. The CoLaus study.   Author/Address of institution Pedro Marques-Vidal 1; Rémy Schmid 1; Murielle Bochud 1; François Bastardot 2; Roland von Känel 3; Fred Paccaud 1; Martin Preisig 4; Gérard Waeber 2 and Peter Vollenweider 2  1 Institute of Social and Preventive Medicine (IUMSP), CHUV and Faculty of biology and medicine, Lausanne; 2 Department of Medicine, Internal Medicine, CHUV and Faculty of biology and medicine, Lausanne; 3 Division of Psychosomatic Medicine, Bern University Hospital Inselspital, and University of Bern; 4 Department of Psychiatry, CHUV, Lausanne, Switzerland   Background/Introduction To assess the prognostic importance of adipocytokine levels (interleukin-1beta - IL-1β; interleukin-6 – IL-6; tumor necrosis factor-α – TNF-α; leptin and adiponectin), acute phase reactants (C-reactive protein - CRP) and gamma-glutamyl transpeptidase (γGT) on the incidence of type 2 diabetes (T2DM).  Methods Prospective study conducted in 3,060 non-diabetic participants (44.6 % men, mean age 52.6±10.6 years), followed for 5 years (2003-2008).  Results 169 patients (5.5%) developed T2DM during follow-up. On univariate analysis, participants who developed T2DM had higher baseline levels of IL-6: median and (interquartile range) 1.51 (0.68–3.27) vs. 1.15 (0.48–2.77) ng/l, p<0.007; CRP: 2.2 (1.2–4.1) vs. 1.1 (0.5–2.4) mg/l, p<0.001; leptin: 11.2 (6.5–21.3) vs. 9.8 (5.3–17.5) µg/l , p<0.02 and γGT: 35 (23–53) vs. 20 (14–30) units/l, p<0.001, and lower levels of adiponectin: 6.21 (4.25–8.44) vs. 8.43 (5.31–13.0) mg/l, p<0.001, than participants who remained free of T2DM. Participants in the highest quartile for IL-6, CRP, leptin and γGT had a higher likelihood of developing T2DM, while the inverse association was found for IL-1β and adiponectin. After adjusting for age, gender and body mass index (BMI), or for known T2DM risk scores, only the associations with γGT and adiponectin remained significant. Finally, including γGT or adiponectin into known T2DM risk scores only modestly increased the area under the curve (0.899 to 0.903 for γGT and 0.897 to 0.901 for adiponectin).  Conclusion Increased adipocytokine and γGT levels are associated with increased risk for T2DM, while adiponectin is inversely associated. It remains to explore whether γGT and adiponectin are only associated or are actually causal factors to the development of diabetes.    26   Different prevalence of childhood abdominal obesity in preschoolers according to the criteria applied    Author/Address of institution Pedro Marques-Vidal 1; Ana Margarida Pinto 2; Flavia Bürgi 3; Vincent Ebenegger 4; Andreas Nydegger 5; Iris Niederer 3; Susi Kriemler 6 and Jardena Puder 7 1 IUMSP, Route de la Corniche 2, 1066 Epalinges; 2 Medical Faculty of Lisbon, Lisbon, Portugal; 3 Institute of Exercise and Health Sciences, University of Basel, Basel; 4 Institute of Sports Sciences, University of Lausanne, Lausanne; 5 Department of Pediatrics, CHUV, Lausanne; 6 Swiss Tropical and Public Health Institute, University of Basel, Basel; 7 Department of Diabetes, CHUV, Lausanne   Background/Introduction Several definitions of pediatric abdominal obesity have been proposed but their respective comparability with body fat has seldom been assessed. Thus, we compared the prevalence of abdominal obesity in an ethnically diverse sample of preschoolers among different waist circumference (WC)-based criteria and assessed their agreement with body fat.  Methods Cross-sectional study of 302 girls and 293 boys aged 4 to 6 years (Ballabeina study). Body fat was assessed by bioimpedance. Children were categorized into those with or without abdominal obesity according to the respective cut-off definitions and into those with or without overall obesity according to McCarthy body fat reference curves of 2006.  Three WC-based criteria (Fernandez, Fredriks and Schwandt) were applied in all children, and a further two (McCarthy and Katzmarzyk) in children aged 5 and over.  Results Prevalence of abdominal obesity according to Fredriks, Fernandez and Schwandt criteria was 4.0%, 5.3% and 7.6% in girls and 4.1%, 6.1% and 7.2% in boys, respectively. Restricting the analysis to children aged 5 and over (191 girls, 162 boys), the prevalence of abdominal obesity in girls was 4.2%, 4.7%, 5.8%, 19.9% and 55.5% according to Fredriks, Fernandez, Schwandt, McCarthy and Katzmarzyk criteria, respectively (3.1%, 4.3%, 6.2%, 23.5% and 49.4% in boys). Using body fat percentage as a reference, the sensitivities [95% confidence interval] were 56.3 [29.9–80.2] (Fernandez); 61.5 [31.6–86.1] (Fredriks); 57.1 [34.0–78.2] (Schwandt); 65.8 [54.0–76.3] (McCarthy) and 73.7 [66.7–79.8] (Katzmarzyk). Specificities were 97.9 [95.8–99.2], 98.5 [96.6–99.5], 97.3 [94.9–98.8], 90.6 [86.5–93.8] and 70.7 [63.1–77.4], respectively.  Conclusion Prevalence of abdominal obesity in young children is heavily dependent on the criteria applied. Efforts should be undertaken to standardize the criteria to define pediatric abdominal obesity. 27   Effect of Ibandronate for the Treatment of Osteonecrosis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial   Author/Address of institution Christian Meier1,2, Claude Kraenzlin2, Niklaus F. Friedrich3, Thorsten Wischer4, Leticia Grize5, Christoph R. Meier6, Marius E. Kraenzlin1,2  1 Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Switzerland;  2 Endocrine Clinic and Laboratory, Basel, Switzerland; 3 Dept. of Orthopedic Surgery, Kantonsspital Bruderholz, Switzerland; 4 Dept. of Radiology, Merian Iselin Hospital, Basel, Switzerland; 5 Biostatistics and Computational Sciences Unit, Dept. of Epidemiology, Public Health Institute Basel, Switzerland; and 6 Division of Clinical Pharmacology and Toxicology, University Hospital, Basel, Switzerland    Background/Introduction Observational studies suggest beneficial effects of bisphosphonates in spontaneous osteonecrosis (ON) of the knee. We investigated whether ibandronate would improve clinical and radiological outcome in newly diagnosed ON.  Methods In this randomized, double-blind, placebo-controlled trial 30 patients (mean age, 57.3±10.7 yrs) with ON were assigned to receive either 12 mg of ibandronate or placebo intravenously (divided into four doses within first 2 weeks). All subjects received additional treatment with oral diclofenac (70 mg) and supplementation with calcium carbonate (500 mg) and vitamin D (400 IU) to be taken daily for 12 weeks. Patients were followed for 48 weeks. The primary outcome was the change in pain score (visual analog scale, VAS) after 12 weeks. Secondary endpoints included changes in VAS, mobility (WOMAC and IKDC questionnaires), biochemical markers of bone turnover, and radiological outcome (MRI) after 24 and 48 weeks.  Results At baseline, both treatment groups (IBN, n=14; placebo, n=16) were comparable in relation to age, BMI, comorbidities, pain score, bone markers, and radiological grading (bone marrow edema, ON). Mean pain score was reduced in both ibandronate (mean change, -3.4; 95%CI, -4.7 to -2.2) and placebo (-3.2; 95%CI, -4.7 to -1.18) treated subjects after 12 weeks (between group comparison, p=ns). Except for significant decrease in bone resorption markers in ibandronate treated subjects (p<0.01), mean changes in all other outcome measures were comparable between treatment groups (after 24 and 48 weeks).   Conclusion We conclude that in patients with spontaneous osteonecrosis of the knee bisphosphonate treatment (i.e. IV ibandronate) has no beneficial effect.  28   Frequency of blood glucose testing in well-educated patients with diabetes mellitus type 1: how often is enough?   Author/Address of institution Anna-Elisabeth Minder, MD, Dominique Albrecht, MD, and Henryk Zulewski, MD Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Petersgraben 4, 4031 Basel   Background/Introduction In people with type 1 diabetes frequent self-monitored blood glucose (SMBG) and patients’ knowledge of individual insulin requirements are pivotal for good metabolic control. How many SMBGs/day are needed for optimal glycaemic control in well-educated patients is not well known.   Methods Retrospective evaluation of HbA1c-values and corresponding frequency of SMBG during a 12 months period in 150 patients with diabetes mellitus type 1 treated with flexible intensified insulin therapy.   Results Median HbA1c was 7.2% (IQR 6.7-7.8%), 63% of the patients reached values ≤7.5%. Median frequency of SMBG was 3.9/day (3.0-4.5). More than 4 SMBGs were associated with best HbA1c-values, without further improvement by >5 SMBGs. Frequency of SMBG and HbA1c was not different in patients experiencing episodes with severe hypoglycaemia in the last 5 years (30.4%) and in those without (69.6%). Median HbA1c was higher in patients with psychological problems than in those without (8.0%  vs. 7.1%, p<0.001) with identical SMBG-frequency (3.9/day). Women had higher HbA1c as men (7.4%  vs. 7.1%, p=0.045), although SMBG-frequency in women was higher (median 3.6 vs. 4.0 times per day, p<0.001).   Conclusion Good diabetes control comparable to CGMS augmented insulin pump therapy is achievable in routine diabetes care in a setting with continuous education based flexible intensified insulin therapy and with >4 SMBGs/day. Other factors such as education, knowledge of insulin requirements and emotional and psychological stability seem to have more impact on glycaemic control than frequency of blood glucose self-monitoring.  Schweizerische Gesellschaft für Endokrinologie und Diabetologie - SGEDSociété Suisse d‘Endocrinologieet de Diabétologie - SSEDJahresversammlungAssemblée annuelle1. und 2. Dezember 2011le 1er et 2 décembre 2011Inselspital Bern20111Contents    pageProgram of the Annual Meeting SGED-SSED   4Program of the Scientific Meeting ASEMO-SAMO   6Oral presentations «Metabolism» – Session 1   8Oral presentations «Pituitary and ...» – Session 2   8Oral presentations «Miscellaneous clinical» – Session 3   9Oral presentations «Beta-cell and ...» – Session 4   10Poster presentations   11Abstracts 14 – 29Traktanden GV / Ordre du jour   30Galadinner   33Sponsoren / Contributeurs   33Plenaries, oral presentations (Ettore Rossi, Kursraum 1), industrial exhibition, lunch/coffee, postersLanghans Auditorium (Pathology), oral presentationsKontaktadresse:Schweizerische Gesellschaft fürEndokrinologie und DiabetologieRütistrasse 3aCH-5400 BadenTel. 056 200 17 50, Fax 056 200 17 95office@sgedssed.ch, www.sgedssed.ch

Adipocytokines and inflammatory biomarkers are independent predictors of type 2 diabetes: the CoLaus study.

https://serval.unil.ch/resource/serval:BIB_664AF0801557.P001/REF.pdf

Adipocytokines and inflammatory biomarkers are independent predictors of type 2 diabetes: the CoLaus study.

Abstract

Similar works

Full text

Available Versions

Bern Open Repository and Information System (BORIS)

Serveur académique lausannois